From: Genomic and immunogenomic analysis of three prognostic signature genes in LUAD
Treatment response | Number | Data sets | Medication regimen | Pathological type |
---|---|---|---|---|
non-responder (SD and PD) | 19 | GEO:GSE135222 | Immunotherapy | Lung non-small cell carcinoma |
responder (CR and PR) | 8 | GEO:GSE135222 | anti-PD-1/PD-L1 | Lung non-small cell carcinoma |
non-responder (SD and PD) | 6 | GEO:GSE126044 | Nivolumab | Lung squamous cell carcinoma |
non-responder (SD and PD) | 5 | GEO:GSE126044 | Nivolumab | LUAD |
responder (CR and PR) | 3 | GEO:GSE126044 | Nivolumab | Lung squamous cell carcinoma |
responder (CR and PR) | 2 | GEO:GSE126044 | Nivolumab | LUAD |